Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
PHASE1CompletedINTERVENTIONAL
Enrollment
42
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
July 31, 2008
Conditions
Recurrent MelanomaRecurrent Renal Cell CancerStage III MelanomaStage IV MelanomaStage IV Renal Cell Cancer
Interventions
BIOLOGICAL
recombinant interferon alfa-2b
Given SC
DRUG
amifostine/azacitidine
Given SC
Trial Locations (1)
06520-8032
Yale University, New Haven
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00217542 - Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter